Goldman Sachs Upgrades Lloyds Banking Group to Neutral

Goldman Sachs analyst Martin Leitgeb upgrades Lloyds Banking Group (NYSE:LYG) from Sell to Neutral.

byBenzinga Newsdesk

September 29, 2021

1 minute read

Goldman Sachs analyst Martin Leitgeb upgrades Lloyds Banking Group (NYSE:LYG) from Sell to Neutral.

Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights

By Vandana Singh

Today, 3:09 PM

Plus Therapeutics Inc (NASDAQ:PSTV) has presented preclinical data of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for leptomeningeal metastases (LM). The…

PSTV

FDA
News

Chemomab Announced FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis

By Charles Gross

Today, 3:09 PM

Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that the U.S.

CMMB

Partner Communications Clocks 2% Revenue Growth In Q2

By Anusuya Lahiri

Today, 3:09 PM

Partner Communications Company Ltd (NASDAQ:PTNR) reported second-quarter FY22 revenue growth of 2% year-on-year to $245 million. Service revenue rose 9% Y/Y…

PTNR

Cheniere Energy Q2 EPS $2.90 Misses $3.17 Estimate, Sales $8.01B Beat $6.39B Estimate

By Bill Haddad

Today, 3:09 PM

Cheniere Energy (AMEX:LNG) reported quarterly earnings of $2.90 per share which missed the analyst consensus estimate of $3.17 by 8.52 percent. This is a 323.08 percent increase over losses of $(1.30) per share from the

LNG

Goldman Sachs Upgrades Lloyds Banking Group to Neutral

Related Posts

Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights

Chemomab Announced FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis

Partner Communications Clocks 2% Revenue Growth In Q2

Cheniere Energy Q2 EPS $2.90 Misses $3.17 Estimate, Sales $8.01B Beat $6.39B Estimate